A once-daily, four-in-one, fixed dose combination pill was listed on the Pharmaceutical Benefits Scheme on 1 May.
Stribild — also referred to as the ‘Quad’ pill — is the third single tablet regimen (STR) to become available to people living with HIV in Australia. Like the other two STRs, Atripla and Eviplera, Stribild is a highly effective antiretroviral (ARV) drug. STRs not only make it easier for PLHIV to remain drug adherent, they also reduce treatment costs.
Stribild combines three active ARVs: a newly licensed integrase inhibitor, elvitegravir; and two reverse transcriptase inhibitors, tenofovir and emtricitabine. The fourth drug in this latest quad combination is a new 'booster' drug, cobicistat. Studies have found Stribild to be well tolerated with few liver effects. As with Eviplera, Stribild must be taken with food.